Beijing Shenogen Biomedical Co., Ltd
4 clinical trials · Sponsor
◉ Watch Beijing Shenogen Biomedical Co., Ltd
| Record | Firm | Date |
|---|---|---|
| Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP) (NCT05594927) | Beijing Shenogen Biomedical Co., Ltd | 2022-12-12 |
| The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects (NCT03236649) | Beijing Shenogen Biomedical Co., Ltd | 2017-09-20 |
| The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects (NCT03236636) | Beijing Shenogen Biomedical Co., Ltd | 2017-09-08 |
Track Beijing Shenogen Biomedical Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.